Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx~* Recurrent disease, incurable disease as determined by surgery or radiation, or metastatic disease~* Measurable or evaluable disease~* Age \> 18 years and \<= 70 years~* WHO performance status 0 or 1~* Absolute neutrophil count \> 1,500/mm3~* Platelets \> 150,000/mm3~* Total Bilirubin \<= institutional upper limit of normal~* Aspartate aminotransferase \< 1.5 X institutional upper limit of normal~* Alanine aminotransferase \< 1.5 X institutional upper limit of normal~* Alkaline phosphatase \< 2.5 X institutional upper limit of normal~* creatinine clearance \> 60 mL/min~* Signed informed consent~* Women of child-bearing potential and men must be willing and able practice adequate contraception prior to study entry and for the duration of study treatment~Exclusion Criteria:~* Previous chemotherapy. Chemotherapy given as part of initial curative therapy and completed more than 6 months before inclusion is allowed~* Previous treatment with total doses of cisplatin \> 300 mg/ m2~* Patients must not have any co-existing disease that would preclude cisplatin administration, such as peripheral neuropathy or renal failure~* Surgery (excluding biopsy) or radiotherapy within 4 weeks prior to study entry~* Nasopharyngeal carcinoma, or cancer of sinusal cavities~* Active infection including tuberculosis or HIV positive patient~* Other malignancy within last 5 years except for non-melanoma skin cancer~* No other investigational agent within 30 days prior to study entry~* No other concurrent chemotherapy, immunotherapy, antitumor hormonal therapy (excluding contraceptives and replacement steroids), radiotherapy, or experimental medications~* No prior anti EGFR therapy~* No known brain metastases~* Uncontrolled intercurrent illness that would prevent delivery of protocol therapy~* Patients with a prior history of basal cell carcinoma of the skin or in situ carcinoma of the cervix must have been curatively treated and must have remained disease free for 5 years post diagnosis~* No history of hypersensitivity reaction to drugs on study~* No unstable angina or myocardial infarction within the past 12 months~* No symptomatic congestive heart failure or New York Heart Association (NYHA) class II-IV heart disease~* No serious uncontrolled cardiac arrhythmia~* No other prior or concomitant squamous cell carcinoma~* No other prior or concomitant cancer, except curatively treated basal carcinoma of the skin or in situ cervical cancer, for which the patient has been curatively treated and remains disease-free for the past 5 years~* Patient is pregnant or lactating~* Patients must not have any co-existing condition that would preclude full compliance with the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- cetuximab (Type: EXPERIMENTAL): Patients receive four cycles of chemotherapy comprising cetuximab IV plus docetaxel IV over 1 hour and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of the fourth cycle of chemotherapy, patients receive a maintenance therapy with cetuximab every 2 weeks. Treatment will be continued until disease progression or unacceptable toxicities according

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete